► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Valeant has agreed to buy Salix, the gastrointestinal specialist, for $14.5bn. Lex's Oliver Ralph and Robert Armstrong discuss whether the serial pharmaceuticals dealmaker's cost-cutting plans are achievable and whether its strategy is sustainable.
► Lex: http://bit.ly/1I14JZF
► FT Business: http://bit.ly/1KUK08s
Make better investment decisions with Lex
http://www.ft.com/lex
Click here for more Lex videos
http://video.ft.com/Lex
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
